Evidence map›Paper›PMID 22578374›Full record

ReviewTransfusion2012

Adverse effects of plasma transfusion.

Suchitra Pandey, Girish N Vyas

6 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Transfusion, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 131 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02460731 phase1completednot on this mapstarted 2015, after this paper: background citation

A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy

TypeinterventionalSponsorUniversity of California, San FranciscoRan2015 to 2019Enrolled6ConditionsProgressive Supranuclear PalsyArmsFresh Frozen Plasma
NCT02557672 phase4completednot on this mapstarted 2016, after this paper: background citation

Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for Post-cardiopulmonary Bypass Coagulopathy and Bleeding, a Prospective Randomized Trial at Large US Medical Center.

TypeinterventionalSponsorMayo ClinicRan2016 to 2022Enrolled106ConditionsBleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex ConcentratesArmsProthrombin complex concentrate (Human), Fresh frozen plasma (FFP)
NCT04174989 nacompletednot on this mapstarted 2020, after this paper: background citation

MULTI-CENTER,DOUBLE-BLIND, RANDOMIZED, TWO-ARMS, CONTROLLED, PROSPECTIVE CLINICAL INVESTIGATION ASSESSING THE SAFETY AND PERFORMANCE OF A CLASS IIb MEDICAL DEVICE (CLEARPLASMATM) FOR THE TREATMENT OF PATIENTS WITH ACUTE UPPER GASTROINTESTINAL HEMORRHAGE.

TypeinterventionalSponsorPlasFree Ltd.Ran2020 to 2022Enrolled53ConditionsAcute Upper Gastrointestinal Hemorrhage, Acute Upper Gastrointestinal BleedingArmsPlasma treated with ClearPlasma (Extra-corporeal plasma filtration device), Regular fresh-frozen plasma (not treated)
NCT04502472 phase2 / phase3terminatednot on this mapstarted 2020, after this paper: background citation

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)

TypeinterventionalSponsorInova Health Care ServicesRan2020 to 2020Enrolled109ConditionsCovid-19ArmsConvalescent plasma transfusion
NCT04521309 phase1 / phase2completednot on this mapstarted 2020, after this paper: background citation

Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients

TypeinterventionalSponsorDow University of Health SciencesRan2020 to 2021Enrolled50ConditionsCOVID-19ArmsSARS-CoV-2 antibody based IVIG therapy
NCT07127718 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Decreasing Leptospirosis Emergence Through Prognosis and Treatment Optimization (DeLEPTO) Project 1: Preventive Strategies for Early and Late Complications of Leptospirosis

TypeinterventionalSponsorNational Kidney and Transplant Institute, PhilippinesRan2024 to 2027Enrolled678ConditionsLeptospirosisArmsProphylactic Plasma Transfusion, Hemoperfusion, Extracorporeal Membrane Oxygenation, Conventional therapy
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Managing bleeds on anticoagulant therapy: a practical guide for clinicians.European heart journal. Acute cardiovascular care · 2026
    Review
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Suchitra PandeyDepartment of Laboratory Medicine, University of California, San Francisco, California 94143, USA.
Girish N Vyas

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
IN VITRO INACTIVATION OF VIRUSES IN BLOOD COMPONENTSR01HL053384 · NHLBI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI VYAS, GIRISH N · 1994 to 1998
–
NHLBI NIH HHS R01 HL053384NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

Plasma utilization has increased over the past two decades, and there is a growing concern that many plasma transfusions are inappropriate. Plasma transfusion is not without risk, and certain complications are more likely with plasma than other blood components. Clinical and laboratory investigations of the patients suffering reactions after infusion of fresh-frozen plasma (FFP) define the etiology and pathogenesis of the panoply of adverse effects. We review here the pathogenesis, diagnosis, and management of the risks associated with plasma transfusion. Risks commonly associated with FFP include: 1) transfusion-related acute lung injury, 2) transfusion-associated circulatory overload, and 3) allergic and/or anaphylactic reactions. Other less common risks include 1) transmission of infections, 2) febrile nonhemolytic transfusion reactions, 3) red blood cell alloimmunization, and 4) hemolytic transfusion reactions. The effects of pathogen inactivation or reduction methods on these risks are also discussed. Fortunately, a majority of the adverse effects are not lethal and are adequately treated in clinical practice.

Indexed as

PlasmaAcute Lung InjuryBlood Component TransfusionErythrocytesGraft vs Host DiseaseHumansHypersensitivityIron Overload

Identifiers

PMID22578374
PMCPMC3356109

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.